Ocular Therapeutix, Inc. (OCUL) vs Zenas BioPharma, Inc. (ZBIO)
A side-by-side comparison of Ocular Therapeutix, Inc. and Zenas BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
OCUL
Ocular Therapeutix, Inc.
$7.32HealthcareDelayed quote: Oct 6, 2026, 3:25 PM EDT
ZBIO
Zenas BioPharma, Inc.
$26.62HealthcareDelayed quote: Oct 6, 2026, 3:25 PM EDT
Total return — OCUL vs ZBIO
growth of $100 · dividends reinvested · last 2yOCUL -18.8% (-9.9%/yr)ZBIO +54.9% (+24.4%/yr)ZBIO compounded faster over this window
OCUL ZBIO
OCUL vs ZBIO: by the numbers
- •ZBIO is the larger company ($1.68B vs $1.60B market cap).
- •Both run net losses; OCUL's is the smaller (-579.10% vs -48438.40% net margin).
Metrics side by side
Valuation
| Metric | OCUL | ZBIO |
|---|---|---|
| P/S ratio | 30.79 | 1680.51 |
| P/B ratio | 3.08 | 6.80 |
Profitability
| Metric | OCUL | ZBIO |
|---|---|---|
| Gross margin | 87.11% | 100.00% |
| Operating margin | -521.04% | -2113.85% |
| Net margin | -579.10% | -48438.40% |
| ROE | -57.97% | -196.03% |
| ROIC | -50.20% | -74.69% |
Growth (annualized)
| Metric | OCUL | ZBIO |
|---|---|---|
| Revenue CAGR (5Y) | 10.03% | N/A |
| Total return CAGR (5Y) | -5.73% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.